The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2009.09.035PMID 19825505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

  2009cited by this paper
• Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials

  2008cited by this paper
• The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.

  2008cited by this paper
• Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.

  2007cited by this paper
• The long-term outcome of medical therapy for BPH.

  2007cited by this paper
• Intraoperative floppy‐iris syndrome associated with α1‐adrenoreceptors: Comparison of tamsulosin and alfuzosin

  2007cited by this paper
• Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.

  2004cited by this paper
• Benign prostatic hyperplasia: a progressive disease of aging men.

  2003cited by this paper
• The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

  2003cited by this paper
• Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

  2002cited by this paper
• Natural history of benign prostatic hyperplasia.

  2001cited by this paper
• THE EFFECT OF FINASTERIDE ON THE RISK OF ACUTE URINARY RETENTION AND THE NEED FOR SURGICAL TREATMENT AMONG MEN WITH BENIGN PROSTATIC HYPERPLASIA

  2000cited by this paper
• Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

  1999cited by this paper
• Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.

  1999cited by this paper
• The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

  1998cited by this paper
• The natural history of benign prostatic hyperplasia.

  1998cited by this paper

• Doxazosin versus tamsulosin for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic literature review and network meta-analysis

  2026cites this paper
• Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial

  2026cites this paper
• Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS.

  2026cites this paper
• Efficacy and safety of α-blockers plus 5α-reductase inhibitors for benign prostatic hyperplasia: a systematic review and meta-analysis.

  2026cites this paper
• Efficacy and Safety of Mirabegron and Tamsulosin Combination Therapy Compared to Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Results of a Multicenter, Randomized, Double-Blind, Phase III Clinical Trial.

  2025cites this paper
• Improving Patient Selection for BPH Medical and Surgical Therapy Through a Deeper Understanding of Prostate Cellular and Molecular Biology.

  2025cites this paper
• Pharmacotherapy for BPH-related LUTS: associations between medication patterns, persistence, and treatment failure

  2025cites this paper
• Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting

  2025cites this paper
• The practical assessment and management of male lower urinary tract symptoms

  2025cites this paper
• Expert consensus on Rezūm™: Indications, surgical technique and postoperative care

  2025cites this paper
• Water Vapor Energy Therapy Safely Reduces Urinary Medication Use: A Multicenter Retrospective Real‐World Study in Japan (SCCOP Study 24‐01)

  2025cites this paper
• Personalized pharmacotherapy for mLUTS - an effective approach to manage OAB symptoms, preserving sexual function and improving quality of life

  2025cites this paper
• Management of patients with lower urinary tract symptoms due to benign prostatic enlargement at risk of progression treated with 5-alpha-reductase inhibitors: examining real-world clinical practice in Spain and Brazil

  2025cites this paper
• Voiding symptom severity varies independently from non-adrenergic prostate smooth muscle contractions in patients undergoing surgery for benign prostatic hyperplasia

  2025cites this paper
• Short- to Mid-term Safety and Efficacy of Prostatic Artery Embolization Using N-Butyl Cyanoacrylate for Symptomatic Benign Prostatic Hyperplasia – A Single-center Experience

  2025cites this paper
• Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights

  2025cites this paper
• Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil

  2025influential citation
• Benigne Prostatahyperplasie mit Blasenentleerungsstörung beim geriatrischen Patienten: Aktive (medikamentöse oder operative) Therapie vs. Katheterversorgung

  2025cites this paper
• Dehydroepiandrosterone Decline in Aging Males as a Predictor of Erectile Dysfunction and Mood Disorders in Patients With Benign Prostate Hyperplasia Undergoing Dutasteride Treatment

  2025influential citation
• Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer.

  2025cites this paper
• Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH).

  2025cites this paper
• An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications

  2025cites this paper
• Penile prosthesis implantation: a systematic review of intraoperative and postoperative complications

  2025influential citation
• Scientific augmentation of BPH and its treatment in Unani medicine the review

  2025cites this paper
• Current management of patients affected by benign prostatic hyperplasia: a multi-institutional study from a contemporary large Italian cohort.

  2025cites this paper
• Paradigm change in the management of benign prostatic hyperplasia

  2025cites this paper
• Predicting early clinical success of prostate artery embolization using MRI perfusion in benign prostatic hyperplasia

  2025cites this paper
• Lower Urinary Tract Symptoms in Men: A Review.

  2025cites this paper
• Burden and determinants of benign prostate hyperplasia in Africa: Systematic review and meta-analysis.

  2025cites this paper
• Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms.

  2025cites this paper
• Traitement non interventionnel des symptômes du bas appareil urinaire liés à l’hyperplasie bénigne de prostate : recommandations de bonne pratique clinique du Comité des troubles mictionnels de l’homme

  2025cites this paper
• Linderung der Blasenauslassobstruktion und Verbesserung der Symptome nach medikamentösen und chirurgischen Therapien bei Symptomen des unteren Harntrakts bei Benignen Prostatasyndrom

  2025cites this paper
• Molecular Profile and Clinical Associations of Androgen Receptor Coactivators and Structural Genes in Benign Prostatic Hyperplasia and Metabolic Syndrome

  2025cites this paper
• The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia

  2025cites this paper
• Real-World Clinical Outcomes of Transperineal Laser Ablation in BPH: A 12-Month Retrospective Analysis

  2025cites this paper
• Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study

  2025cites this paper
• Pine-Extracted Phytosterol β-Sitosterol (APOPROSTAT® Forte) Inhibits Both Human Prostate Smooth Muscle Contraction and Prostate Stromal Cell Growth, Without Cytotoxic Effects: A Mechanistic Link to Clinical Efficacy in LUTS/BPH

  2025cites this paper
• Combination Pharmacotherapy for Benign Prostatic Hyperplasia: Evaluation of Existing Literature on Combination Therapies for Lower Urinary Tract Symptoms Associated with BPH

  2025influential citation
• Current pharmacotheraupeutical options of lower urinary tract symptoms.

  2025cites this paper
• Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update

  2024cites this paper
• Prostate Artery Embolization (PAE) with Small Beads for the Treatment of Benign Prostatic Hyperplasia (BPH)

  2024cites this paper
• Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese

  2024cites this paper
• Tamsulosin 0.8 mg daily dose in management of BPH patients with failed tamsulosin 0.4 mg monotherapy and unfit for surgical intervention

  2024cites this paper
• Predictors for surgical treatment in male patients with non-neurogenic lower urinary tract symptoms (LUTS)

  2024cites this paper
• Does ejaculation have an effect on urinary flow rates?

  2024cites this paper
• The Impact of Combination Therapy of Croton membranaceus and Finasteride on Benign Prostatic Hyperplasia (BHP) Histo-morphology

  2024cites this paper
• Comparing monotherapy with tadalafil or tamsulosin in men with benign prostatic hyperplasia: A case–control study

  2024cites this paper
• The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trial

  2024cites this paper
• Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

  2024cites this paper
• How to navigate drug shortages with patients in primary care

  2024cites this paper
• Teverelix is a potential treatment option for the prevention of acute urinary retention recurrence in men suffering from benign prostatic hyperplasia

  2024cites this paper
• Comination pharmacotherapy of lower urinary tract symptoms

  2024cites this paper
• The human microbiome and benign prostatic hyperplasia: Current understandings and clinical implications.

  2024cites this paper
• Is there a best timing for benign prostatic hyperplasia surgery?

  2024cites this paper
• Decoding the complexity of benign prostatic hyperplasia therapies in the PARTEM trial

  2024cites this paper
• Gut Microbiota Disorders in Obesity-Associated Benign Prostatic Hyperplasia in Rats

  2024influential citation
• Efficacy of Prunus africana, Urtica dioica and Epilobium angustifolium in patients with benign prostatic hyperplasia

  2024cites this paper
• Paradigm change in the management of benign prostatic hyperplasia.

  2024cites this paper
• Decoding the complexity of benign prostatic hyperplasia therapies in the PARTEM trial—authors’ reply

  2024cites this paper
• Recent developments in diagnostic ultrasound for lower urinary tract function.

  2024cites this paper
• Do 5-Alpha Reductase Inhibitors Influence the Features of Suspicious Lesions on Magnetic Resonance Imaging and Targeted Biopsy Results for Prostate Cancer Diagnosis?

  2024cites this paper
• Autophagy in benign prostatic hyperplasia: insights and therapeutic potential

  2024cites this paper
• The Assessment of Patient-Reported Outcomes in the Medical Management of Patients With Benign Prostatic Hyperplasia

  2024cites this paper
• Tamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription

  2024cites this paper
• Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia

  2024cites this paper
• Uroselective α1A-Adrenoceptor Antagonist Tamsulosin in Treatment Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia

  2024cites this paper
• Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach.

  2024cites this paper
• The ‘Prostate Embolisation AS first‐line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial’ (P‐EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH

  2024cites this paper
• Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5‐alpha reductase inhibitor resistance

  2024cites this paper
• Non-inferiority, randomised, open-label clinical trial on the effectiveness of transurethral microwave thermotherapy compared to prostatic artery embolisation in reducing severe lower urinary tract symptoms in men with benign prostatic hyperplasia: study protocol for the TUMT-PAE-1 trial

  2024cites this paper
• Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

  2024cites this paper
• α1-adrenoceptor antagonists and 5α-reductase inhibitors for urinary tract symptoms in benign prostatic hyperplasia

  2024cites this paper
• Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial

  2024cites this paper
• The post-finasteride syndrome: possible etiological mechanisms and symptoms

  2023cites this paper
• Treating LUTS in Men with Benign Prostatic Obstruction: A Review Article

  2023cites this paper
• Safety and efficacy of tamsulosin 0.4 mg as an initial dose in 1,219 Korean patients with moderate to severe lower urinary tract symptoms: data from a phase IV study

  2023cites this paper
• Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review

  2023cites this paper
• Adrenoceptors in the Lower Urinary Tract.

  2023cites this paper
• Adverse events related to alpha-blockers: analysis of real-life data from Eudra-Vigilance.

  2023cites this paper
• Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.

  2023cites this paper
• The Cardiovascular Safety of 5-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.

  2023cites this paper
• MRI of Benign Prostatic Hyperplasia: Important Pre- and Posttherapeutic Considerations.

  2023cites this paper
• Targeting androgen receptor in glioblastoma.

  2023cites this paper
• Long‐term risk of benign prostatic hyperplasia‐related surgery and acute urinary retention in men treated with 5‐alpha reductase inhibitor versus alpha‐blocker monotherapy in routine clinical care

  2023influential citation
• Is prostatic artery embolization a relevant treatment after a failed alpha-blocker monotherapy?—Authors’ reply

  2023cites this paper
• A prospective evaluation of the effect of finasteride on prostate health index (phi)

  2023cites this paper
• α1-Adrenergic Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer’s Disease

  2023cites this paper
• 5-alpha reductase inhibitors use in prostatic disease and beyond

  2023cites this paper
• Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia

  2023cites this paper
• Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders

  2023cites this paper
• Bladder calculi concomitant with benign prostatic enlargement: is prostate surgery mandatory in patients who have never received medical therapy?

  2023cites this paper
• Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

  2023cites this paper
• The role of the bladder diary in phenotyping men with LUTS

  2023cites this paper
• Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study

  2023influential citation
• Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial

  2023cites this paper
• Research Progress on Gels-Based Nanocomposites in the Diagnostics and Therapy of Prostate Diseases

  2023cites this paper
• Expression and functional activity of myosin II in hyperplastic prostates of varying volumes.

  2023cites this paper
• Risks and side effects in the medical management of benign prostatic hyperplasia

  2023cites this paper
• Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia

  2023cites this paper
• Exploring the effects and mechanism of peony pollen in treating benign prostatic hyperplasia

  2023cites this paper